ImmunityBio (NASDAQ:IBRX) Shares Down 9.2% – Here’s Why

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price traded down 9.2% during mid-day trading on Thursday . The company traded as low as $7.45 and last traded at $7.3090. 6,173,525 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 29,679,039 shares. The stock had previously closed at $8.05.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio said a health economic analysis presented at ISPOR 2026 showed ANKTIVA plus BCG delivered a lower cost per sustained complete responder than TAR-200 in BCG-unresponsive NMIBC CIS, a potentially supportive commercial and reimbursement datapoint. Article Title
• Neutral Sentiment: Several broker and research notes remained constructive, including reports of buy ratings from BTIG Research and HC Wainwright, which may help offset some of the negative sentiment around the stock. Article Title
• Neutral Sentiment: News also noted that Anktiva label expansion is undergoing FDA review, which could be a future catalyst if approved, but it remains uncertain for now. Article Title
• Negative Sentiment: A large cluster of law-firm notices and deadline reminders emphasized the May 26 lead-plaintiff deadline in an existing securities class action, reinforcing investor focus on alleged disclosures around ImmunityBio’s Anktiva claims. Article Title
• Negative Sentiment: The lawsuit background centers on an FDA warning letter that allegedly challenged unsupported efficacy claims, a headline that has weighed on sentiment and triggered broader legal scrutiny. Article Title

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of ImmunityBio in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Stock Down 6.7%

The business’s 50 day simple moving average is $7.75 and its two-hundred day simple moving average is $5.58. The stock has a market cap of $7.56 billion, a P/E ratio of -8.49 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to analysts’ expectations of $43.07 million. As a group, research analysts forecast that ImmunityBio, Inc. will post -0.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the transaction, the director owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 265,000 shares of company stock worth $2,842,000. Insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of ImmunityBio by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after purchasing an additional 5,122,052 shares during the period. State Street Corp lifted its holdings in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after purchasing an additional 5,139,890 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ImmunityBio by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after purchasing an additional 1,030,113 shares during the period. Heights Capital Management Inc. acquired a new position in shares of ImmunityBio during the third quarter worth $16,152,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after purchasing an additional 5,012,001 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.